RT Journal Article
SR Electronic
T1 Probable Cerebral Amyloid Angiopathy–Related Inflammation Associated With Sitravatinib
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP e4
OP e6
DO 10.1212/CPJ.0000000000001162
VO 12
IS 2
A1 Ray, Christopher
A1 Dionne, Kalen
YR 2022
UL http://cp.neurology.org/content/12/2/e4.abstract
AB Background and Objectives We present the case of a 67-year-old man who developed encephalopathy, headaches, and seizure activity after initiating treatment with the novel tyrosine kinase inhibitor, sitravatinib.Methods The patient was identified in routine clinical practice.Results Brain MRI revealed lobar microhemorrhages and bihemispheric vasogenic edema. The patient met the criteria for probable cerebral amyloid angiopathy–related inflammation (CAA-ri) and responded favorably to high-dose methylprednisolone.Discussion This report of neurologic autoimmunity in a patient receiving sitravatinib opens new lines of inquiry into the pathophysiology of CAA-ri. We emphasize the importance of early recognition and treatment of CAA-ri among patients receiving immunomodulatory chemotherapy.